Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
21.55
-0.45 (-2.07%)
At close: May 22, 2026, 4:00 PM EDT
21.59
+0.04 (0.21%)
After-hours: May 22, 2026, 4:10 PM EDT
Forte Biosciences Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Forte Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $63.75. The average 1-year stock price forecast is 195.89% higher than the current stock price, while the lowest is $54 (+150.64%) and the highest is $75 (+248.11%).
Price Target: $63.75 (+195.89%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 25, 2025.
Analyst Ratings
The average analyst rating for Forte Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $65 | Buy | Initiates | $65 | +201.69% | Nov 25, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $61 | Strong Buy | Maintains | $61 | +183.13% | Nov 17, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $75 | Strong Buy | Initiates | $75 | +248.11% | Aug 18, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $61 | Strong Buy | Maintains | $61 | +183.13% | Aug 15, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $61 | Strong Buy | Maintains | $61 | +183.13% | Jun 24, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.43
from -4.71
EPS Next Year
-4.37
from -4.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -4.24 | -3.03 | ||||||
| Avg | -4.43 | -4.37 | ||||||
| Low | -4.58 | -5.79 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.